Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)

被引：23

作者：

Moreno, Maria ^{[1
,2
]}

Mol, Berber M. ^{[1
]}

von Mensdorff-Pouilly, Silvia ^{[2
]}

Verheijen, Rene H. M. ^{[3
]}

von Blomberg, B. Mary E. ^{[1
]}

van den Eertwegh, Alfons J. M. ^{[4
]}

Scheper, Rik J. ^{[1
]}

Bontkes, Hetty J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Dept Obstet & Gynaecol, NL-1081 HV Amsterdam, Netherlands

[3] Univ Med Ctr Utrecht, Dept Woman & Baby, Div Surg & Oncol Gynaecol, Utrecht, Netherlands

[4] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands

来源：

CANCER LETTERS | 2008年 / 272卷 / 01期

关键词：

Human; Invariant NKT cells; Toll-like receptors; NK cells; ADCC;

D O I：

10.1016/j.canlet.2008.06.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

huHMFG-1 (AS1402) is a humanised IgG1 against MUC1, which exerts tumour cell killing through antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Here, we explored the capacity of invariant NKT (iNKT) cells, which are known to activate NK cells, and toll-like receptor (TLR) ligands which activate both iNKT and NK cells, to enhance huHMFG-1-ADCC. Addition of iNKT cells, as well as TLR2/6, 7, 8 and 9 agonists to PBMC improved the efficacy of huHMFG-1. These results suggest that transfer of ex vivo expanded iNKT cells or TLR agonist treatment may improve the efficacy of NK cell-mediated antibody-based tumour immunotherapies. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：70 / 76

页数：7

共 50 条

[21] HUMAN MONOCYTE, LYMPHOCYTE, AND GRANULOCYTE ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) TO TUMOR-CELLS
LEVY, P
SHAW, G
LOBUGLIO, A
CLINICAL RESEARCH, 1978, 26 (05): : A686 - A686
[22] CELL-MEDIATED CYTOTOXICITY (CMC) AND ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) BY SPLEEN LYMPHOCYTES FROM VACCINIA INFECTED HAMSTERS
WOAN, MC
TOMPKINS, WAF
FEDERATION PROCEEDINGS, 1978, 37 (06) : 1379 - 1379
[23] A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay
Singh, Karnail
Marasini, Bishal
Chen, Xuemin
Spearman, Paul
JOURNAL OF IMMUNOLOGICAL METHODS, 2018, 460 : 10 - 16
[24] HUMAN MONOCYTE, LYMPHOCYTE, AND GRANULOCYTE ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) TO TUMOR-CELLS
LEVY, P
SHAW, G
LOBUGLIO, A
CLINICAL RESEARCH, 1979, 27 (04): : A719 - A719
[25] HUMAN MONOCYTE, LYMPHOCYTE, AND GRANULOCYTE ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) TO TUMOR-CELLS
LEVY, P
SHAW, G
LOBUGLIO, A
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 134 - 134
[26] EFFECTS OF LY-5 ANTIBODIES ON ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
SMALL, RM
WALDEN, SM
EWALD, SJ
IMMUNOLOGY, 1987, 60 (02) : 159 - 165
[27] ANTIBODY-DEPENDENT CELL CYTOTOXICITY (ADCC) - CHARACTERIZATION OF KILLER CELLS IN HUMAN LYMPHOID ORGANS
CORDIER, G
SAMARUT, C
BROCHIER, J
REVILLARD, JP
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1976, 5 (03) : 233 - 242
[28] Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay
Chen, Xuemin
Anderson, Larry J.
Rostad, Christina A.
Ding, Lingmei
Lai, Lilin
Mulligan, Mark
Rouphael, Nadine
Natrajan, Muktha S.
McCracken, Courtney
Anderson, Evan J.
JOURNAL OF IMMUNOLOGICAL METHODS, 2021, 488
[29] HETEROGENEITY OF LYMPHOID FC RECEPTORS AND THEIR RELATIONSHIP TO ANTIBODY-DEPENDENT, CELL-MEDIATED CYTOTOXICITY (ADCC)
GORMUS, BJ
KAPLAN, ME
CLINICAL RESEARCH, 1976, 24 (03): : A328 - A328
[30] KILLER (K)-CELLS RESPONSIBLE FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY EXPRESS HUMAN T LYMPHOCYTE ANTIGENS
KAPLAN, J
PEDIATRIC RESEARCH, 1978, 12 (04) : 481 - 481

← 1 2 3 4 5 →